High-performance liquid chromatographic determination of 2',3'-dideoxycytidine and 3'-azido-3'-deoxythymidine in plasma using a column-switching technique. 1988

L E Mathes, and G Muschik, and L Demby, and P Polas, and D W Mellini, and H J Issaq, and R Sams
Department of Veterinary Pathobiology, Ohio State University, Columbus 43210.

UI MeSH Term Description Entries
D012015 Reference Standards A basis of value established for the measure of quantity, weight, extent or quality, e.g. weight standards, standard solutions, methods, techniques, and procedures used in diagnosis and therapy. Standard Preparations,Standards, Reference,Preparations, Standard,Standardization,Standards,Preparation, Standard,Reference Standard,Standard Preparation,Standard, Reference
D002415 Cats The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801) Felis catus,Felis domesticus,Domestic Cats,Felis domestica,Felis sylvestris catus,Cat,Cat, Domestic,Cats, Domestic,Domestic Cat
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015224 Dideoxynucleosides Nucleosides that have two hydroxy groups removed from the sugar moiety. The majority of these compounds have broad-spectrum antiretroviral activity due to their action as antimetabolites. The nucleosides are phosphorylated intracellularly to their 5'-triphosphates and act as chain-terminating inhibitors of viral reverse transcription. 2',3'-Dideoxynucleosides,Dideoxyribonucleosides,ddNus,2',3' Dideoxynucleosides
D016047 Zalcitabine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy. 2',3'-Dideoxycytidine,Dideoxycytidine,ddC (Antiviral),HIVID Roche,Hivid,NSC-606170,2',3' Dideoxycytidine,NSC 606170,NSC606170

Related Publications

L E Mathes, and G Muschik, and L Demby, and P Polas, and D W Mellini, and H J Issaq, and R Sams
December 1990, Journal of chromatography,
L E Mathes, and G Muschik, and L Demby, and P Polas, and D W Mellini, and H J Issaq, and R Sams
July 1992, Journal of chromatography,
L E Mathes, and G Muschik, and L Demby, and P Polas, and D W Mellini, and H J Issaq, and R Sams
July 1993, Journal of chromatography,
L E Mathes, and G Muschik, and L Demby, and P Polas, and D W Mellini, and H J Issaq, and R Sams
April 2001, Journal of chromatography. B, Biomedical sciences and applications,
L E Mathes, and G Muschik, and L Demby, and P Polas, and D W Mellini, and H J Issaq, and R Sams
November 1989, Archiv der Pharmazie,
L E Mathes, and G Muschik, and L Demby, and P Polas, and D W Mellini, and H J Issaq, and R Sams
February 1992, Journal of chromatography,
L E Mathes, and G Muschik, and L Demby, and P Polas, and D W Mellini, and H J Issaq, and R Sams
April 2001, Journal of chromatography. B, Biomedical sciences and applications,
L E Mathes, and G Muschik, and L Demby, and P Polas, and D W Mellini, and H J Issaq, and R Sams
June 2000, Journal of chromatography. B, Biomedical sciences and applications,
L E Mathes, and G Muschik, and L Demby, and P Polas, and D W Mellini, and H J Issaq, and R Sams
August 1988, Clinical chemistry,
L E Mathes, and G Muschik, and L Demby, and P Polas, and D W Mellini, and H J Issaq, and R Sams
February 1996, Journal of chromatography. B, Biomedical applications,
Copied contents to your clipboard!